Payer Briefs: Express Scripts Pricing Pilot; HHS Risk Adjustment; Value Frameworks
This article was originally published in The Pink Sheet Daily
Executive Summary
Indication-based pricing experiment by Express Scripts gets off to a quiet start; HHS makes progress on factoring Rx spending in its risk adjustment calculations for ACA plans and the National Pharmaceutical Council releases recommended standards for drug value assessments.
You may also be interested in...
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.